PEER-REVIEW | DERMATOLOGY |
Table 1 Patient feedback at respective visit
CHARACTERISTIC DESCRIPTION Skin
hydration Skin
tone Skin
luminity
Drier than before/less dry /no change
More tan/fairer/no change
More dull/more radiant /no change
Table 2 Patient demographics VARIABLES
GENDER Female 269 Male 14
RACE
Chinese 228 Malay 30 Indian 10 Filipino 11 Vietnamese 1 Burmese 2 Caucasian 1
PATIENT MEDIAN AGE 33 TOTAL PATIENTS 283
Aim of study
The aim of the study was to evaluate the skin hydrating and whitening effects of Vit C and GSH by reporting patients’ assessment and overall satisfaction after a course of six Vit C and GSH injections. For this study, skin hydration referred to making skin less dry and more moist. Skin whitening referred to making skin either fairer or more radiant or both.
Material and method Study participants The medical records of consecutive patients newly enrolled between 1 st January to 31 st December 2014 were selected for this study. Inclusion criteria were: First visit for Vit C and GSH injection fell between 1 st January 2014 to 31 st December 2014
Completed six Vit C and GSH injections Of the six Vit C and GSH injections, the interval between each injection must be equal or less than 10 days.
24 October 2015 |
prime-journal.com
Material used The vitamin C solution used for injection was under the brand Laroscorbine® 1 g/5 ml (Bayer Sante Familiale, larosrcobine, Gaillard, France). The glutathione powder used for injection was under the brand Tationil® 600 mg/4 ml, (Teoforma , Tationil, Salimbene, Italy).
Method of injection One vial of glutathione powder (600 mg) was mixed with 10 ml of vitamin C solution (2 g) in a 10 ml syringe. The constituted glutathione/vitamin C solution was injected intravenously into the patient via a Surflo® winged infusion set 23G x 3/4” (Terumo Corporation, Surflo®, Tokyo, Japan). The constituted solution was injected slowly over 5 minutes. Injections sites were either right cubital fossa, left
NUMBER OF PATIENTS
cubital fossa, dorsum of right hand or dorsum of left hand. The same doctor constituted the solution and administered the injection to the patient.
Treatment protocol Patients were given an injection once every 7–10 days, a total of six times. The first injection was given during the first visit and assessment.
The vitamin C
solution used for injection was
under the brand Laroscorbine® 1 g/5 ml.
Method of assessment Skin assessment of the face and all limbs at first visit was noted clinically by visual assessment and the patient’s main complaints were recorded. For the purpose of the study, the skin parameters were divided into: Normal hydration or dry Fair or tan Radiant or dull. The first Vit C and GSH injection was
given during the first visit. During the second to sixth visit, the patients reported on how they felt about their skin condition over the period of time from the last
injection up to the current visit to the clinic. Patients reported whether their skin conditions were
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72